Gastrointestinal Symptoms
Gastrointestinal symptoms are extremely common in ME/CFS, with estimates suggesting 70–90% of patients experience significant GI dysfunction.
1 Nausea
Clinical Presentation.
- Chronic or recurrent nausea
- Nausea triggered by exertion, movement, or sensory stimulation
- Medication-induced nausea (many ME/CFS patients have heightened sensitivity)
- Early satiety (feeling full quickly)
- Food aversions
2 Irritable Bowel Syndrome (IBS)
Clinical Presentation.
- Abdominal pain or cramping
- Diarrhea (IBS-D), constipation (IBS-C), or alternating patterns (IBS-M)
- Bloating and gas
- Urgency or incomplete evacuation
- Symptoms worsening with stress or certain foods
Mechanism. IBS in ME/CFS likely involves gut dysbiosis, mast cell activation in the GI tract, autonomic dysfunction affecting gut motility, and visceral hypersensitivity (central amplification of gut sensations).
3 Food Intolerances and Sensitivities
Common Triggers.
- Gluten (celiac disease or non-celiac gluten sensitivity)
- Dairy/lactose
- FODMAPs (fermentable carbohydrates)
- Histamine-rich foods (aged cheese, fermented foods, cured meats)
- Specific proteins (nuts, eggs, soy)
- Artificial additives and preservatives
Symptom Response.
- Gastrointestinal symptoms (bloating, pain, diarrhea)
- Systemic symptoms (fatigue, brain fog, headache)
- Allergic-type reactions
- PEM-like exacerbations
4 Gastroparesis and Delayed Gastric Emptying
Clinical Presentation.
- Feeling full after small amounts of food
- Persistent nausea
- Vomiting (especially of undigested food)
- Abdominal bloating and discomfort
- Unpredictable blood sugar fluctuations
Mechanism. Gastroparesis reflects autonomic dysfunction affecting the vagus nerve, which controls gastric motility. Impaired stomach emptying creates digestive symptoms and nutritional challenges.
A controlled radionuclide study measured gastric emptying in 32 people with chronic fatigue syndrome and found delayed liquid emptying in 23/32 (72%) and delayed solid emptying in 12/32 (38%); the emptying delay correlated significantly with the mean symptom score (p \(<\) 0.001) (Burnet and Chatterton 2004). This is direct ME/CFS evidence that delayed gastric emptying is a real, measurable feature of the illness, not merely a subjective complaint. The finding has not been replicated in a modern-IOM/ICC-criteria cohort, and the study predates current diagnostic criteria. (Raw certainty: 0.60, direct ME/CFS population → no discount.) (Certainty: 0.60.)
(Evidence source: radionuclide gastric emptying scintigraphy — direct measurement of the target organ.)
(Translation gap: none — measured gastric emptying directly in the target population.)
(Diagnostic criteria: CDC-1994-era CFS, criteria not precisely stated; pre-dates IOM 2015 / ICC 2011.)
(Severity applicability: not stratified — study population severity not reported.)
Consequence: Delayed stomach emptying is a measurable, evidence-based problem in ME/CFS — not a vague symptom — which means it can be assessed with a standard gastric emptying test and may be a target for treatment rather than something patients must simply endure.
A single adolescent CFS case report found normal gastric emptying and myoelectrical activity (Corrado et al. 1998), indicating delayed emptying is not universal in the illness; the case is low-evidentiary (n = 1, pediatric) and does not negate the larger cohort finding above.
In diabetic and idiopathic gastroparesis, human gastric antral tissue shows loss of the pacemaker cells of the stomach (interstitial cells of Cajal), reduced enteric nerve fibres, and altered resident macrophages (Grover et al. 2011); an animal model of diabetic gastroparesis confirms that loss of these cells and nerves is accompanied by slowed gastric emptying (Wang et al. 2009). Whether ME/CFS gastroparesis involves the same structural degeneration is unknown — no ME/CFS gastric histology has been published, so the ME/CFS form could reflect functional vagal failure alone, autoimmune ganglionic blockade, or structural enteric/pacemaker-cell loss. (Raw certainty: 0.52, cross-disease general population → this is a mechanistic question, certainty is the strength of the non-ME/CFS substrate; the final 0.40 reflects that the structural pathology is demonstrated in non-ME/CFS gastroparesis but unverified in ME/CFS.) (Certainty: 0.40.)
(Translation gap: Grover 2011 and Wang 2009 studied diabetic/idiopathic gastroparesis, not ME/CFS; cross-disease inference to ME/CFS is unvalidated.)
(Competing mechanism: the same symptom pattern can be explained by functional dyspepsia with abnormal gastric accommodation and visceral hypersensitivity rather than true delayed emptying — see (Debourdeau et al. 2024).)
(Severity applicability: unknown — not stratified in the source studies.)
Falsifiable prediction: A gastric antral biopsy or full-thickness specimen from ME/CFS patients with documented gastroparesis showing normal interstitial-cell-of-Cajal and enteric-nerve density would falsify the claim that ME/CFS gastroparesis shares the structural degeneration of diabetic/idiopathic gastroparesis; evidence of cell/nerve loss would support it.
Consequence: If ME/CFS gastroparesis turns out to involve structural loss of the stomach’s pacemaker cells rather than only functional vagal failure, then prokinetic drugs that stimulate remaining nerves would have limits, and treatment would need to target prevention or replacement of that cell loss instead.
Prokinetic drugs are the main pharmacological option for gastroparesis and are evidence-based in the general gastroparesis population (Ingrosso et al. 2023), but they carry serious risks that are especially relevant to severe/very-severe ME/CFS patients:
- Metoclopramide is the only FDA-approved drug for gastroparesis but carries a black-box warning for use beyond 12 weeks because of tardive dyskinesia, which may be irreversible; it also causes drowsiness, restlessness, and hyperprolactinaemia (Shakhatreh et al. 2019).
- Domperidone can prolong the cardiac QT interval — a baseline ECG/QT assessment and QTc monitoring are prudent before and during use — and erythromycin (as a motilin agonist) loses effectiveness with prolonged use through receptor desensitization; see the network meta-analysis for comparative adverse-effect data (Ingrosso et al. 2023).
- Highly selective 5-HT4 agonists (e.g. prucalopride) show efficacy with no excess pooled cardiovascular/QT signal in trials (Patel et al. 2024), but are not approved for gastroparesis in all jurisdictions.
- GLP-1 receptor agonists are contraindicated in established gastroparesis — they decelerate gastric emptying in humans (Nauck et al. 2011) and are a recognised cause of medication-induced gastroparesis (Camilleri and Jencks 2025); they also suppress appetite and can worsen weight loss and nausea, all of which are already problematic in severe ME/CFS (see also the GLP-1/area-postrema concern Area Postrema as a Possible Gate — an Untested Autoantibody × GLP-1 Hypothesis). If emptying delay began after the drug started, a clinician may consider a supervised trial hold or discontinuation, which in some cases resolves the picture; that is a clinical judgement, not established guidance. Never stop a prescribed GLP-1 without a clinician. Their use in a patient with gastroparesis requires explicit review against this risk.
In ME/CFS no prokinetic has been tested in a controlled trial, so dosing and safety must be extrapolated from other populations. For severe/very-severe patients, an evidence-based trial with the lowest-risk agent, close monitoring for extrapyramidal, cardiac, and autonomic effects, and explicit time-limited use is the cautious approach; prokinetics do not treat the underlying autonomic dysfunction and are best combined with dietary measures (Gupta and Lee 2016). (Evidence type: general-population clinical evidence; ME/CFS-specific efficacy unproven.)
(Severity applicability: the safety cautions apply with particular force to severe/very-severe patients, for whom polypharmacy and autonomic instability raise risk; evidence is not severity-stratified.)
(Drug interactions: macrolide prokinetics (erythromycin) and domperidone are CYP3A4-modulating / QT-prolonging and must be checked against ME/CFS co-prescriptions — domperidone adds arrhythmia risk with QT-prolonging agents (trazodone, amitriptyline); erythromycin raises levels of CYP3A4 substrates (including fludrocortisone) and carries QT risk; metoclopramide is dopaminergic and can worsen extrapyramidal effects alongside other dopamine-modulating drugs. A full interaction review against the individual patient’s medication list is required before use; interaction data were checked via adverse-effect literature for these agents.)
(Pregnancy/lactation: metoclopramide, domperidone, and erythromycin cross the placenta and enter breast milk; safety in pregnancy/lactation for gastroparesis use is not established in the ME/CFS population — no pregnancy/lactation safety data specific to this indication exist, so use in pregnancy/lactation requires specialist review.)
(No ME/CFS-specific monitoring protocol exists; general clinical monitoring and time-limited use recommended.)
Consequence: Prokinetics can genuinely help gastroparesis, but in ME/CFS they must be used with explicit safety checks — the most effective drug (metoclopramide) is also the riskiest over time, so safe use means choosing the lowest-risk option and not continuing indefinitely.
Cross-disease perspective. Gastroparesis is a well-characterized complication of diabetes mellitus and is increasingly recognized in the post-viral setting. Autoimmune gastrointestinal dysmotility has been reported after SARS-CoV-2 infection, presenting with intractable nausea, early satiety, delayed gastric emptying, and antibodies against ganglionic acetylcholine receptors, with improvement after immunotherapy (Montalvo et al. 2022). In the autonomic/hypermobility overlap (POTS, hypermobile Ehlers–Danlos syndrome), GI dysmotility and gastroparesis are common and can require non-oral nutritional support in severe cases (Tseng et al. 2019) (Aziz et al. 2025). These parallels support gastroparesis as a plausible manifestation of the autonomic and autoimmune dysfunction implicated in ME/CFS, and as a source of nutritional risk in severe illness.
A case of autoimmune gastrointestinal dysmotility after SARS-CoV-2 infection presented with intractable nausea, early satiety, delayed gastric emptying, and antibodies against α3 nicotinic ganglionic acetylcholine receptors, and improved substantially with immunotherapy (Montalvo et al. 2022). By analogy, a subset of ME/CFS patients with gastroparesis could have an autoimmune ganglionic (vagal/enteric) blockade rather than structural nerve loss — a mechanism that would be potentially reversible with immunotherapy rather than irreversible. This is speculative for ME/CFS: no ME/CFS cohort has been screened for ganglionic AChR antibodies, and the autoimmune GI dysmotility literature in ME/CFS is a single post-viral case report. (Raw certainty: 0.45, post-viral/Long COVID case → weighted 0.85, discounted to 0.38; further reduced to 0.30 for the single-case origin and the unvalidated ME/CFS-transfer step.) (Certainty: 0.30.)
(Translation gap: the ganglionic-AChR-blockade mechanism is demonstrated in a single post-SARS-CoV-2 case, not in ME/CFS; the autoantibody target (α3 nicotinic ganglionic AChR) has not been measured in ME/CFS.)(Competing mechanism: functional vagal failure, structural enteric/pacemaker-cell loss, or medication effects could produce the same symptom pattern without any autoimmune component — see Does ME/CFS Gastroparesis Share the Enteric-Nerve and Pacemaker-Cell Loss Seen in Diabetic and Idiopathic Gastroparesis?. This GI manifestation parallels the pan-autonomic ganglionic-AChR hypothesis Ganglionic AChR Autoantibodies in Pan-Autonomic ME/CFS Subtype — Autoimmune Autonomic Ganglionopathy Overlap — gastroparesis may be one downstream expression of the same autoantibody mechanism.)
(Severity applicability: unknown — single case, not severity-stratified.)
Falsifiable prediction: Measuring ganglionic acetylcholine-receptor antibodies (α3, β4) in a cohort of ME/CFS patients with documented gastroparesis — if a meaningful subset is antibody-positive AND shows objective emptying improvement after immunotherapy, the autoimmune-blockade claim is supported; if antibody titers do not track emptying delay or immunotherapy response, it is falsified.
Origin: brainstorm (idea 1.1).
Consequence: If a fraction of ME/CFS gastroparesis turned out to be an autoimmune, reversible process, that subset of patients would have a real treatment path (immunotherapy) rather than only symptom management — this is testable with an existing blood antibody panel.
For moderate-to-severe gastroparesis, dietary modification and feeding strategy are the first-line, lowest-risk interventions: small frequent meals, low-fat and low-fibre meals to reduce the gastric mechanical load, and liquid or semi-liquid nutrient options when solid emptying is slow (Gupta and Lee 2016). In the autonomic/POTS population, GI dysmotility with feeding intolerance is a recognized driver of the need for non-oral (enteral or parenteral) nutritional support in the most affected patients (Tseng et al. 2019). These measures do not reverse the underlying autonomic dysfunction but are essential to maintain nutrition and avoid avoidable weight loss in severe/very-severe ME/CFS. (Evidence type: general-population clinical guidance + POTS-cohort evidence; ME/CFS-specific validation absent.)
(Severity applicability: the dietary and liquid-nutrient measures apply across severity; enteral escalation is a very-severe/feeding-failure measure.)
Consequence: For severe patients who cannot keep down enough food, simple dietary changes and liquid nutrition are the safest first step before any drug — they protect weight and energy without the risks of prokinetics, and severe cases that still cannot feed need a formal escalation plan to enteral support.
The direct evidence that ME/CFS patients have delayed gastric emptying rests largely on a single 2004 cohort (n = 32) that predates modern diagnostic criteria (Burnet and Chatterton 2004); the one direct null case is a single adolescent (Corrado et al. 1998), and no modern-IOM/ICC-criteria cohort has replicated the finding. Several non-specific explanations could produce the same symptom pattern without a distinct ME/CFS gastroparesis lesion: medication side-effects (many ME/CFS drugs slow gastric emptying), functional dyspepsia with abnormal accommodation and visceral hypersensitivity rather than true emptying delay (Debourdeau et al. 2024), deconditioning or severe-illness effects, and subjective reporting bias inflating symptom-based prevalence estimates. Cross-disease mechanistic support (diabetic/idiopathic gastroparesis histology (Grover et al. 2011), animal models (Wang et al. 2009)) is heavily population-discounted and does not by itself establish that ME/CFS shares that pathology. (Certainty: this is a limitation/risk assessment, not a positive claim.)
(Severity applicability: the caution applies across all severities; the single anchor cohort was not severity-stratified.)
Consequence: Before acting on the gastroparesis diagnosis in ME/CFS, clinicians should recognize the evidence is a single old cohort and exclude the common non-specific causes (drug effects, dyspepsia) with objective testing rather than assuming a distinct ME/CFS-specific emptying defect.
Taken together, the evidence establishes that delayed gastric emptying is a real, measurable feature of ME/CFS — not a vague complaint — with a documented cohort finding Delayed Gastric Emptying Is Documented in a ME/CFS Cohort, Correlating With Symptom Severity and a vagal-cascade context in ch34 Autonomic Hypotheses (which draws on the same cohort plus HRV/vagal-tone literature rather than independent emptying replication). What remains genuinely unresolved is the mechanism: whether ME/CFS gastroparesis reflects structural enteric/pacemaker-cell loss, autoimmune ganglionic blockade, or functional vagal failure — the open question and speculation above Does ME/CFS Gastroparesis Share the Enteric-Nerve and Pacemaker-Cell Loss Seen in Diabetic and Idiopathic Gastroparesis? Autoimmune Ganglionic Acetylcholine-Receptor Blockade Could Be a Reversible Cause of Some ME/CFS Gastroparesis. This uncertainty does not leave clinicians empty-handed: the evidence supports a safe, first-line nutritional pathway Nutritional Management Is the First-Line, Lowest-Risk Intervention — Especially for Severe Cases and a carefully safety-managed prokinetic option Prokinetic Use for Gastroparesis Requires Careful Safety Management — Especially in Severe ME/CFS, provided the substantial evidence limitations are respected Gastroparesis Evidence in ME/CFS Is Anchored on One Old, Unreplicated Cohort — and Non-Specific Alternative Explanations Exist. The single most actionable conclusion for a severe case is: treat the measurable problem with the lowest-risk measures first, confirm emptying objectively, and do not assume a specific lesion until it is demonstrated.
Consequence: For patients and clinicians, the convergent message is practical — gastroparesis in ME/CFS is real and testable, and there is a safe treatment ladder to start with (diet + nutrition first, cautious prokinetics second) while the underlying mechanism remains an open research question rather than a barrier to care.
(Severity applicability: aggregates the per-environment severities — the documented-emptying finding and management guidance apply most strongly to moderate/severe/very-severe patients, for whom nutritional-failure risk is highest; the underlying evidence is not severity-stratified.)
5 Gastroesophageal Reflux (GERD)
Clinical Presentation.
- Heartburn and acid reflux
- Regurgitation
- Difficulty swallowing (dysphagia)
- Chronic cough or throat clearing
- Worsening when lying down